logo
Plus   Neg
Share
Email

BioXcel Therapeutics Inc. (BTAI) Is Up After FDA Fast Track Designation

BioXcel Therapeutics Inc. (BTAI) announced Thursday morning that it has been granted Fast Track Designation by the FDA for BXCL501, for the treatment of acute agitation.

BioXcel Therapeutics gapped up at the open Thursday and has risen sharply in early trade. Shares are now up 2.43 at $4.84 on above average volume. The stock has jumped to a 2-week high.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>